Skip to main content

Day: June 3, 2020

Mkango Announces Resignation of Non Executive Director

LONDON and VANCOUVER, British Columbia, June 03, 2020 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM/TSX-V: MKA) (the “Company” or “Mkango“) regrets to announce that, because of new work commitments, Sandra du Toit has stepped down as a Non Executive Director of the Company.Derek Linfield, Chairman of Mkango, stated: “On behalf of the Board and our shareholders, I would like to thank Sandra for her significant contributions to the development of the business during her time as a Director. I would also like to congratulate Sandra on her new role and wish her all the best for the future.”For further information on Mkango, please contact:Mkango Resources LimitedThe TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation...

Continue reading

Middlesex Water Employee Donations Support Coronavirus Relief

ISELIN, N.J., June 03, 2020 (GLOBE NEWSWIRE) — Middlesex Water Company (NASDAQ: MSEX), has announced that through its COVID-19 relief efforts, to date, the Company and its employees have contributed over $61,000 to fourteen separate organizations in New Jersey and Delaware.  The donations from employees have been in the form of cash or equivalent cash for donated back vacation days and have been matched two-for-one by Middlesex Water and Tidewater Utilities, Inc., its largest Delaware subsidiary.“As protectors of public health, safety and economic stability, we’re committed to supporting the health and well-being of the communities we serve.  In addition to providing reliable utility services to help our customers cope during this crisis, we’re pleased to be able help equip first responders with personal protective equipment and...

Continue reading

Maroc Telecom_Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social_Mai 2020

                                                                 Information mensuelle relative au nombre total de droits de voteet d’actions composant le capital socialAu 29 mai 2020Article 223-16 du Règlement Général de l’Autorité des Marchés FinanciersPlaces de cotation :– Bourse de Casablanca : Marché principal / MA 0000011488– Euronext Paris : Eurolist (valeurs étrangères) / MA 0000011488– LEI : 254900LH0G1ZIZ78Y462–    Présence dans les statuts de Maroc Telecom d’une clause imposant l’obligation de déclaration de franchissement de seuil complémentaire de celle relative aux seuils légaux : OUIAvenue Annakhil, Hay Riad Rabat MAROCTel + 212 (0) 537 71 21 21 / fax + 212 537 71 48 60Itissalat Al Maghrib – Maroc Telecom : Société anonyme à Directoire et à Conseil de surveillance au capital de 5.274.572.040...

Continue reading

Orphan Drugs Market to Surpass US$ 125,016.1 Mn by 2025, Pfizer’s Strong Distribution Network to Enable it Establish a Stronghold Worldwide, states Fortune Business Insights

Pune, June 03, 2020 (GLOBE NEWSWIRE) — The rising prevalence for chronic diseases is a major factor expected to drive the global orphan drugs market during the forecast period. Fortune Business Insights in a recent report, titled “Orphan Drugs Market Size, Share and Global Trend by Therapy Area (Oncology, Haematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy), Drug Type (Biologics, Non-Biologics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Geography Forecast till 2025” published the above information. In the base year i.e. 2017, the global market was accounted for US$ 125,016.1 Mn and is estimated to reach US$ 294,037.8 Mn by forecast year i.e. 2025. Furthermore, the global market is anticipated to exhibit a CAGR of 11.4 % throughout the forecast years.The demand for oncology...

Continue reading

Providence Resources P.l.c. – 2019 Annual Results

Providence Resources P.l.c. – 2019 Annual ResultsDublin and London – June 3, 2020 – Providence Resources P.l.c. (PVR LN, PRP ID), the Irish based Energy company, today announces its Annual Results for the year ended December 31, 2019.FINANCIAL HIGHLIGHTSOperating loss for the period of €25.936 million versus €4.425 million in 2018Loss for the year of €26.853 million versus €4.779 million in 2018Loss per share of 4.39 cents versus 0.80 cents in 2018At 31 December 2019 total cash and cash equivalents were €0.710 million versus €7.617 million (at 31 December 2018)The Company had no debt at 31 December 2019The total issued and voting share capital comprises 835,397,852 ordinary shares of €0.001 each as at 2 June 20202019 REVIEWThe international operating environment for the oil and gas sector was relatively stable in 2019 with commodity...

Continue reading

Karolinska Development’s portfolio company Aprea Therapeutics completes enrollment in Phase 3 study of eprenetapopt

STOCKHOLM, SWEDEN – June 3, 2020. Karolinska Development AB’s (Nasdaq Stockholm: KDEV) portfolio company Aprea Therapeutics announced today that it has completed enrollment in a Phase 3 clinical trial evaluating eprenetapopt with azacitidine for the treatment of front-line TP53 mutant myelodysplastic syndromes (MDS). Topline results are expected by year-end 2020. Aprea plans to include the results of the trial in a New Drug Application (NDA) to the U.S. FDA and a Marketing Authorization Application (MAA) to the EMA in 2021.The randomized, controlled pivotal Phase 3 trial is designed to evaluate eprenetapopt with azacitidine compared with azacitidine alone as front-line therapy in intermediate, high, and very high risk TP53 mutant MDS patients. The multi-center trial enrolled 154 patients, randomized 1:1 to the two arms with a primary...

Continue reading

Karolinska Developments portföljbolag Aprea Therapeutics har slutfört rekryteringen av patienter till en fas 3-studie av eprenatapopt

STOCKHOLM, SVERIGE 3 juni 2020. Karolinska Development AB:s (Nasdaq Stockholm: KDEV) portföljbolag Aprea Therapeutics meddelade idag att man har slutfört rekryteringen i en fas 3-studie för utvärdering av läkemedelskandidaten eprenatapopt i kombination med azacitidine i patienter med TP53-muterat myelodysplastiskt syndrom (MDS). Topline-resultat förväntas kunna redovisas i slutet av 2020. Aprea planerar att inkludera studieresultaten i registreringsansökningar till den amerikanska läkemedelsmyndigheten FDA och dess europeiska motsvarighet EMA, vilka förväntas lämnas in under 2021.Den randomiserade, kontrollerade registreringsgrundande fas 3-studien är utformad för att utvärdera eprenetapopt i kombination med azacitidine, jämfört med azacitidine som monoterapi som en första linjens behandling för patienter med olika grad av muterat TP53...

Continue reading

INGENICO GROUP: PSD2 – Ingenico’s new SCA Accelerator Suite speeds up compliance

Ingenico’s new SCA Accelerator Suite speeds up complianceThe new authentication suite helps online businesses improve their performance and streamline the implementation of SCAIngenico Group (Euronext: FR0000125346 – ING), the global leader in seamless payments, today unveils its SCA accelerator suite to help online businesses remain compliant, innovate and better control their data. The suite will bring all of Ingenico ePayments’ expertise together to help online businesses improve their performance and facilitate the implementation of Strong Customer Authentication (SCA), due on 31 December 2020.The SCA Accelerator Suite from Ingenico utilizes the latest versions of 3D Secure, ensures businesses are compliant with The EU Second Payment Services Directive (PSD2), offers authentication routing, ensures the appropriate data collection...

Continue reading

INGENICO GROUP : DSP2 – Ingenico lance une nouvelle gamme pour accélérer la mise en conformité sur l’authentification forte du client (SCA)

DSP2 : Ingenico lance une nouvelle gamme pour accélérer la mise en conformité sur l’authentification forte du client (SCA)Cette nouvelle gamme d’authentification permettra aux acteurs en ligne d’améliorer leurs performances et de rationaliser la mise en œuvre de l’authentification forte du client (SCA)Ingenico Group (Euronext: FR0000125346 – ING), leader mondial des solutions de paiement intégrées lance aujourd’hui sa gamme SCA accelerator, pour aider les entreprises en ligne à rester conformes, à innover et à mieux contrôler leurs données. S’appuyant sur l’expertise d’Ingenico ePayments, elle permettra d’accompagner de la meilleure manière les entreprises en ligne, pour améliorer leurs performances et faciliter la mise en œuvre de la SCA, prévue au 31 décembre 2020.La gamme « SCA Accelerator » d’Ingenico...

Continue reading

Apple Rush Company, Inc. updates progress on Japan Distribution

TITUSVILLE, Fla., June 03, 2020 (GLOBE NEWSWIRE) — The Apple Rush Company, Inc. (US OTC PINK: APRU), updates its shareholders on our progress on Japanese distribution.The company has been working for several months on a distribution deal in Japan.  The process of gaining approval in Japan required very specific information in both formulation and processing of our flagship product. Quarantine in Japan (equivalent to our FDA) requires that all ingredient suppliers provide all of the components with percentages to them for safety verification and validation.  The information required was substantial and proprietary but the company was successful in gaining access to everything needed for the application.  “I am excited by the fact that we have been able to get through the next phase of the approval process.   Our partners provided...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.